18.44 +0.01 (0.05%)
After hours: 4:24PM EDT
|Bid||18.42 x 2200|
|Ask||18.42 x 800|
|Day's range||18.41 - 18.58|
|52-week range||12.43 - 20.93|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||22.71|
|Forward dividend & yield||0.84 (4.56%)|
|Ex-dividend date||30 Mar 2020|
|1y target est||23.44|
The results provide more justification for the FDA to grant the substance emergency use authorization.
Takeda today presented three abstracts at the 72nd National Hemophilia Foundation’s Bleeding Disorders Conference.
Japan's Takeda Pharmaceutical Co on Friday raised its full-year profit forecast as it refocuses on its core prescription drug businesses following its $59 billion takeover of Shire Plc last year. Japan's largest drugmaker by revenue expects operating profit of 395 billion yen ($3.78 billion) in the year to March 2021, it said on Friday in reporting quarterly earnings. The revision to its forecast was mainly due to one-time items, Takeda said.